Heyman Richard A. 4
4 · Oric Pharmaceuticals, Inc. · Filed Oct 3, 2025
Insider Transaction Report
Form 4
Heyman Richard A.
Director
Transactions
- Exercise/Conversion
Common Stock
2025-10-03$1.60/sh+31,353$50,165→ 43,853 total - Exercise/Conversion
Common Stock
2025-10-03$3.75/sh+1,447$5,426→ 45,300 total - Exercise/Conversion
Stock Option (right to buy)
2025-10-03−1,447→ 52,253 totalExercise: $3.75Exp: 2032-06-16→ Common Stock (1,447 underlying) - Exercise/Conversion
Stock Option (right to buy)
2025-10-03−13,228→ 33,700 totalExercise: $1.60Exp: 2028-02-28→ Common Stock (13,228 underlying) - Exercise/Conversion
Stock Option (right to buy)
2025-10-03−18,125→ 0 totalExercise: $1.60Exp: 2028-06-28→ Common Stock (18,125 underlying)
Holdings
- 216,272(indirect: See footnote)
Common Stock
Footnotes (2)
- [F1]The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares.
- [F2]The shares subject to the option are fully vested and immediately exercisable.